Cliff Asness’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $219M | Sell |
728,039
-185,065
| -20% | -$55.8M | 0.08% | 357 |
|
|
2026
Q1 | $298M | Sell |
913,104
-6,855
| -0.7% | -$2.33M | 0.14% | 202 |
|
|
2025
Q4 | $366M | Buy |
919,959
+175,951
| +24% | +$77.9M | 0.19% | 120 |
|
|
2025
Q3 | $336M | Buy |
744,008
+555,759
| +295% | +$226M | 0.22% | 98 |
|
|
2025
Q2 | $61.3M | Sell |
188,249
-640,095
| -77% | -$177M | 0.05% | 484 |
|
|
2025
Q1 | $217M | Buy |
828,344
+14,988
| +2% | +$3.85M | 0.22% | 101 |
|
|
2024
Q4 | $191M | Buy |
813,356
+307,702
| +61% | +$80.9M | 0.25% | 76 |
|
|
2024
Q3 | $139M | Buy |
505,654
+234,035
| +86% | +$60.9M | 0.19% | 122 |
|
|
2024
Q2 | $65.9M | Buy |
271,619
+130,482
| +92% | +$20.6M | 0.1% | 246 |
|
|
2024
Q1 | $21.1M | Buy |
141,137
+127,117
| +907% | +$21.2M | 0.04% | 510 |
|
|
2023
Q4 | $2.68M | Buy |
14,020
+4,560
| +48% | +$777K | 0.01% | 1214 |
|
|
2023
Q3 | $1.66M | Buy |
9,460
+3,726
| +65% | +$711K | ﹤0.01% | 1405 |
|
|
2023
Q2 | $1.09M | Sell |
5,734
-373
| -6% | -$74K | ﹤0.01% | 1517 |
|
|
2023
Q1 | $1.21M | Buy |
+6,107
| New | +$1.28M | ﹤0.01% | 1472 |
|
|
2022
Q4 | – | Sell |
-11,768
| Closed | -$2.35M | – | 2199 |
|
|
2022
Q3 | $2.35M | Buy |
11,768
+5,754
| +96% | +$1.1M | 0.01% | 1135 |
|
|
2022
Q2 | $865K | Sell |
6,014
-5,233
| -47% | -$742K | ﹤0.01% | 1478 |
|
|
2022
Q1 | $1.84M | Buy |
11,247
+9,123
| +430% | +$1.39M | ﹤0.01% | 1229 |
|
|
2021
Q4 | $360K | Buy |
+2,124
| New | +$395K | ﹤0.01% | 1928 |
|
|
2021
Q2 | – | Sell |
-1,914
| Closed | -$269K | – | 2218 |
|
|
2021
Q1 | $269K | Sell |
1,914
-37,733
| -95% | -$5.68M | ﹤0.01% | 2041 |
|
|
2020
Q4 | $5.09M | Sell |
39,647
-32,134
| -45% | -$4.29M | 0.01% | 783 |
|
|
2020
Q3 | $10.3M | Sell |
71,781
-23,400
| -25% | -$3.33M | 0.02% | 627 |
|
|
2020
Q2 | $14.1M | Buy |
95,181
+48,963
| +106% | +$6.6M | 0.02% | 555 |
|
|
2020
Q1 | $5.03M | Buy |
+46,218
| New | +$5.33M | 0.01% | 775 |
|
|
2019
Q2 | – | Sell |
-2,367
| Closed | -$221K | – | 2063 |
|
|
2019
Q1 | $221K | Buy |
+2,367
| New | +$198K | ﹤0.01% | 2048 |
|
|
2018
Q4 | – | Sell |
-9,638
| Closed | -$844K | – | 2180 |
|
|
2018
Q3 | $844K | Sell |
9,638
-4,249
| -31% | -$427K | ﹤0.01% | 1764 |
|
|
2018
Q2 | $1.37M | Sell |
13,887
-334
| -2% | -$33.1K | ﹤0.01% | 1592 |
|
|
2018
Q1 | $1.69M | Buy |
14,221
+7,676
| +117% | +$990K | ﹤0.01% | 1435 |
|
|
2017
Q4 | $832K | Buy |
+6,545
| New | +$822K | ﹤0.01% | 1735 |
|
|
2017
Q1 | – | Sell |
-27,669
| Closed | -$1.04M | – | 2170 |
|
|
2016
Q4 | $1.04M | Buy |
+27,669
| New | +$1.16M | ﹤0.01% | 1679 |
|
|
2016
Q2 | – | Sell |
-3,739
| Closed | -$235K | – | 2193 |
|
|
2016
Q1 | $235K | Sell |
3,739
-212,939
| -98% | -$14.2M | ﹤0.01% | 2069 |
|
|
2015
Q4 | $20.4M | Buy |
216,678
+62,887
| +41% | +$5.83M | 0.04% | 544 |
|
|
2015
Q3 | $12.4M | Buy |
153,791
+71,679
| +87% | +$7.96M | 0.02% | 575 |
|
|
2015
Q2 | $9.84M | Buy |
82,112
+34,764
| +73% | +$4.15M | 0.02% | 614 |
|
|
2015
Q1 | $4.94M | Buy |
47,348
+28,979
| +158% | +$2.94M | 0.01% | 783 |
|
|
2014
Q4 | $1.78M | Sell |
18,369
-11,900
| -39% | -$1.1M | ﹤0.01% | 1349 |
|
|
2014
Q3 | $2.36M | Buy |
30,269
+2,264
| +8% | +$146K | 0.01% | 1176 |
|
|
2014
Q2 | $1.77M | Buy |
28,005
+6,800
| +32% | +$404K | ﹤0.01% | 1359 |
|
|
2014
Q1 | $1.42M | Sell |
21,205
-2,200
| -9% | -$170K | ﹤0.01% | 1504 |
|
|
2013
Q4 | $1.51M | Sell |
23,405
-20,878
| -47% | -$1.25M | ﹤0.01% | 1519 |
|
|
2013
Q3 | $2.83M | Sell |
44,283
-211
| -0.5% | -$10.5K | 0.01% | 1083 |
|
|
2013
Q2 | $1.38M | Buy |
+44,494
| New | +$1.18M | ﹤0.01% | 1411 |
|
Other funds holding ALNY
Cliff Asness's ALNY Position: Q2 2026 in Review
Cliff Asness reduced its Alnylam Pharmaceuticals (ALNY) stake by 20% in Q2 2026, selling an estimated $55.8M and leaving 728,039 shares worth $219M. The position accounts for 0.08% of the portfolio, ranked #357.
Cliff Asness first reported a position in ALNY in Q2 2013 and has held it in 41 quarters since. The position peaked at $366M in Q4 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Cliff Asness held 728,039 shares of Alnylam Pharmaceuticals worth $219M as of Q2 2026.
- Cliff Asness sold 185,065 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $55.8M.
- Alnylam Pharmaceuticals made up 0.08% of Cliff Asness's portfolio in Q2 2026, its #357 holding.
- Cliff Asness first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
- Cliff Asness's Alnylam Pharmaceuticals position peaked at $366M in Q4 2025.
- 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.